As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S ...

Novo Nordisk will pay all the research and development costs for the project. The U.S. biotech company has developed a platform that finds and develops drugs that target special proteins called G ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that longtime CEO Lars Fruergaard ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. Stream San Diego News for free, 24/7, wherever you are with NBC 7. The Danish ...

As a pioneer in diabetes care, Novo Nordisk has been in the business for ... or a larger acquisition that might add more debt to the capital structure (which could lower Novo's cost of capital).

May 16 - As Denmark's Novo Nordisk shops for its next CEO to replace ... said on Friday its current CEO will step down over concerns the company is losing its first-mover advantage in the highly ...

Novo Nordisk’s chairman Helge Lund said the company’s strategy remains unchanged, and it is confident in its current business plans. The search for a successor is underway. Meanwhile ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...